Glioblastoma Multiforme (GBM) - Competitive Landscape
Description
Glioblastoma Multiforme (GBM) - Competitive Landscape
Summary
This reports provides a data-driven overview of the current and future competitive landscape in GBM therapeutics.
- More than 79,000 incident cases of GBM are anticipated in 2023 in the 16 countries covered in GlobalData’s epidemiology forecast for GBM.
- Only a handful of innovator treatment options approved for GBM, the current major player in the GBM market is Roche.
- Out of 803 molecules in the pipeline for GBM, 19 drugs are in Phase III and 171 drugs are in Phase II.
- The clinical trial space in GBM is a mix of commercial as well as academic sponsors, with the US emerging as the key country for conducting Phase III trials.
- In deals involving companies developing GBM assets, partnerships were the most prominent deals type ventured globally.
GlobalData’s GBM: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the GBM market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global GBM market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
75 Pages
- Key Findings
- Disease Etiology Symptoms
- Epidemiology Overview – Incident Cases of GBM in 2023 and 2028
- Treatment Guidelines
- Marketed Drugs – Leading Marketed Drugs in GBM
- Marketed Drugs – Overview by Mechanism of Action
- Marketed Drugs – Overview by Route of Administration
- Marketed Drugs – Overview by Molecule Type
- Marketed Drug Profile – Roche's Avastin
- Marketed Drugs – Annual Cost of Therapy
- Marketed Drugs – Time to Pricing for Avastin
- Pipeline Drugs Overview – Late-Stage Pipeline Drugs in GBM
- Pipeline Drugs – Overview by Development Stage
- Pipeline Drugs – Overview by Mechanism of Action
- Pipeline Drugs – Overview by Route of Administration
- Pipeline Drugs – Overview by Molecule Type
- Pipeline Drugs – Phase Transition Success Rate and Likelihood of Approval in GBM
- Pipeline Drugs – Phase Transition Success Rate and Likelihood of Approval in Oncology and GBM
- Clinical Trials in GBM – Historical Overview
- Clinical Trials in GBM – Overview by Phase
- Clinical Trials in GBM – Overview by Status
- Clinical Trials in GBM – Overview by Phase for Ongoing and Planned Trials
- Clinical Trials in GBM – Trials with a Virtual Component
- Clinical Trials in GBM – Geographic Overview
- Clinical Trials in GBM – Single-Country and Multinational Trials by Region
- Clinical Trials in GBM – Top Sponsors with Breakdown by Phase
- Clinical Trials in GBM – Top Sponsors with Breakdown by Status
- Clinical Trials in GBM – Overview by Endpoint Status
- Clinical Trials in GBM – Overview by Race and Ethnicity
- Clinical Trials in GBM – Enrollment Data
- Clinical Trials in GBM – Overview of Sites by Geography
- Clinical Trials in GBM – Top 20 Countries for Trial Sites
- Clinical Trials in GBM – Top 20 Sites Globally
- Clinical Trials – Feasibility Analysis: Geography Overview
- Clinical Trials – Feasibility Analysis: Benchmark Models for GBM
- Deals Landscape – Mergers, Acquisitions, and Strategic Alliances in GBM by Region
- Deals Landscape – Recent Mergers, Acquisitions, and Strategic Alliances in GBM
- Commercial Assessment – Key Market Players in GBM
- Future Market Catalysts – Upcoming Market Catalysts in GBM
- Methodology
- Methodology – Sales Forecasts
- Methodology – Pricing and Reimbursement
- Methodology – Phase Transition Success Rate and Likelihood of Approval Analysis
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
